VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

BCG-DHTM
Vaccine Information
  • Vaccine Name: BCG-DHTM
  • Target Pathogen: Mycobacterium tuberculosis
  • Target Disease: Tuberculosis
  • Vaccine Ontology ID: VO_0004618
  • Type: Recombinant vector vaccine
  • Status: Research
  • Antigen: BCG vaccine with deficient urease; a fusion protein composed of Mycobacterium tuberculosis-derived major membrane protein II (MMP-II) and heat shock protein 70 (HSP70) of BCG (Mukai et al., 2014).
  • DnaK gene engineering:
    • Type: Recombinant vector construction
    • Description: The M. tuberculosis gene dnaK, also known as hsp70, is a part of a fusion gene composed of the M. tuberculosis-derived MMP-II gene and the hsp70 gene of M. tuberculosis (locus tag: Rv0350). This fusion gene is introduced into the urease-deficient BCG-deltaUT-11-3 strain (Mukai et al., 2014).
    • Detailed Gene Information: Click Here.
  • bfrA gene engineering:
    • Type: Recombinant vector construction
    • Description: The M. tuberculosis gene bfrA (also known as MMP-II) is a part of a fusion gene composed of the M. tuberculosis-derived MMP-II gene and the hsp70 gene of M. tuberculosis (locus tag: Rv0350). This fusion gene is introduced into the urease-deficient BCG-deltaUT-11-3 strain (Mukai et al., 2014).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Immunization Route: subcutaneous injection
Host Response

Mouse Response

  • Host Strain: C57BL/6J
  • Host age: 5 weeks
  • Vaccination Protocol: Five mice per group were vaccinated with BCG-261H (control) or BCG-DHTM at 1000 CFU/mouse for 6 weeks (Mukai et al., 2014)
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Mice were challenged with H37RV at 100 CFU per lung by aerosol infection (Mukai et al., 2014)
  • Efficacy: At 6 weeks post challenge, mice vaccinated with BCG-261H (control) or BCG-DHTM showed inhibited multiplication of M. tuberculosis in the lung, and BCG-DHTM inhibited M. tuberculosis multiplication more strongly than BCG-261H (Mukai et al., 2014).
  • Information about this animal model: Mouse Model for TB research
References
Mukai et al., 2014: Mukai T, Tsukamoto Y, Maeda Y, Tamura T, Makino M. Efficient activation of human T cells of both CD4 and CD8 subsets by urease-deficient recombinant Mycobacterium bovis BCG that produced a heat shock protein 70-M. tuberculosis-derived major membrane protein II fusion protein. Clinical and vaccine immunology : CVI. 2014; 21(1); 1-11. [PubMed: 24152387].